Redefining Obesity & the Implications for Drug Development in the PostLancet Commission Era to Improve Patient Treatment for More Effective Weight Management
Time: 8:30 am
day: Day One
Details:
- Redefining obesity beyond BMI, emphasizing health outcomes and moving towards a more personalized approach based on the Lancet Commission on Obesity’s recommendations
- Prioritizing targets that address the underlying causes of clinical obesity and its complications, developing personalized therapies, and emphasizing clinical endpoints that reflect improved health outcomes
- Understanding the challenges of implementing this new approach, such as developing accurate diagnostic tools and addressing the complexities of personalized medicine as well as highlighting the significant opportunities for innovation and improved patient outcomes Charlie Harris Associate Vice President Eli Lilly
